{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T21:07:54Z","timestamp":1774645674859,"version":"3.50.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T00:00:00Z","timestamp":1679270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T00:00:00Z","timestamp":1679270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01-AR0703015"],"award-info":[{"award-number":["R01-AR0703015"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008070","name":"Department of Medicine, University of California, San Francisco","doi-asserted-by":"publisher","award":["Robert L. Kroc Chair in Rheumatic"],"award-info":[{"award-number":["Robert L. Kroc Chair in Rheumatic"]}],"id":[{"id":"10.13039\/100008070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008070","name":"Department of Medicine, University of California, San Francisco","doi-asserted-by":"publisher","award":["Connective Tissue Diseases III"],"award-info":[{"award-number":["Connective Tissue Diseases III"]}],"id":[{"id":"10.13039\/100008070","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disorder associated with increased immune activity and severe, progressive heterotopic ossification. We previously described a cohort of 32 patients with FOP who were either exposed to SARS-CoV-2 or received a COVID-19 vaccine<jats:sup>1<\/jats:sup> and showed that these patients did not develop heterotopic ossification after COVID-19 vaccination. Here, we present additional clinical data from new subjects and additional long-term follow-up from the first cohort. We enrolled 15 new subjects between August 24th, 2021 and May 17th, 2022 and collected additional self-reported outcomes. The larger cohort with 47 individuals encompassing 49 events showed that patients with FOP exhibited no additional change in FOP disease activity or flare activity resulting from COVID-19 infection or after receipt of a SARS-CoV-2 vaccine. Thus, although any vaccination carries a risk of inducing heterotopic ossification in patients with FOP, our results show that patients with FOP who choose to receive a COVID-19 vaccination may be able to tolerate the procedure without a high risk of heterotopic ossification when following the published guidelines.<\/jats:p>","DOI":"10.1186\/s13023-023-02638-0","type":"journal-article","created":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T08:03:14Z","timestamp":1679299394000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A follow-up report on the published paper Social and clinical impact of COVID-19 on patients with fibrodysplasia ossificans progressiva"],"prefix":"10.1186","volume":"18","author":[{"given":"Hayley","family":"Wallace","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhonda H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8924-106X","authenticated-orcid":false,"given":"Edward C.","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,20]]},"reference":[{"issue":"1","key":"2638_CR1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13023-022-02246-4","volume":"17","author":"S Kou","year":"2022","unstructured":"Kou S, Kile S, Kambampati SS, Brady EC, Wallace H, De Sousa CM, et al. Social and clinical impact of COVID-19 on patients with fibrodysplasia ossificans progressive. Orphanet J Rare Dis. 2022;17(1):107.","journal-title":"Orphanet J Rare Dis"},{"key":"2638_CR2","unstructured":"International Clinical Council (ICC) on Fibrodysplasia Ossificans Progressiva (FOP). 2022. Guidelines\u2014International Clinical Council (ICC) on Fibrodysplasia Ossificans Progressiva (FOP). https:\/\/www.iccfop.org\/guidelines\/. Accessed 23 September 2022."},{"issue":"2","key":"2638_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.29245\/2572-9411\/2020\/2.1196","volume":"5","author":"M Liljesthr\u00f6m","year":"2020","unstructured":"Liljesthr\u00f6m M, Pignolo R, Kaplan F. Epidemiology of the Global Fibrodysplasia Ossificans Progressiva (FOP) community. J Rare Dis Res Treat. 2020;5(2):31\u20136.","journal-title":"J Rare Dis Res Treat"},{"issue":"5","key":"2638_CR4","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/S0022-3476(95)70408-6","volume":"126","author":"T Lanchoney","year":"1995","unstructured":"Lanchoney T, Cohen R, Rocke D, Zasloff M, Kaplan F. Permanent heterotopic ossification at the injection site after diphtheria-tetanus-pertussis immunizations in children who have fibrodysplasia ossificans progressiva. J Pediatr. 1995;126(5):762\u20134.","journal-title":"J Pediatr"},{"key":"2638_CR5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/01.blo.0000129557.38803.26","volume":"423","author":"R Scarlett","year":"2004","unstructured":"Scarlett R, Rocke D, Kantanie S, Patel J, Shore E, Kaplan F. Influenza-like viral illnesses and flare-ups of fibrodysplasia ossificans progressiva. Clin Orthop Relat Res. 2004;423:275\u20139.","journal-title":"Clin Orthop Relat Res"},{"issue":"8","key":"2638_CR6","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1007\/s00296-021-04911-6","volume":"41","author":"L Grgurevic","year":"2021","unstructured":"Grgurevic L, Novak R, Hrkac S, Salai G, Grazio S. Post-COVID-19 exacerbation of fibrodysplasia ossificans progressiva with multiple flare-ups and extensive heterotopic ossification in a 45-year-old female patient. Rheumatol Int. 2021;41(8):1495\u2013501.","journal-title":"Rheumatol Int"},{"key":"2638_CR7","doi-asserted-by":"publisher","first-page":"116287","DOI":"10.1016\/j.bone.2021.116287","volume":"155","author":"ML Brance","year":"2022","unstructured":"Brance ML, C\u00f3ccaro NM, Casalongue AN, Dur\u00e1n A, Brun LR. Extensive progressive heterotopic ossification post-covid-19 in a man. Bone. 2022;155:116287.","journal-title":"Bone"},{"issue":"7","key":"2638_CR8","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.cmi.2020.12.037","volume":"27","author":"E Stoira","year":"2021","unstructured":"Stoira E, Elzi L, Puligheddu C, Garibaldi R, Voinea C, Chiesa AF, et al. High prevalence of heterotopic ossification in critically ill patients with severe COVID-19. Clin Microbiol Infect. 2021;27(7):1049\u201350.","journal-title":"Clin Microbiol Infect"},{"key":"2638_CR9","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3389\/fimmu.2022.1017232","volume":"13","author":"J Smetanova","year":"2022","unstructured":"Smetanova J, Milota T, Rataj M, Hurnakova J, Zelena H, Horvath R. SARS-COV-2-specific humoral and cellular immune responses to BNT162B2 vaccine in fibrodysplasia ossificans progressiva patients. Front Immunol. 2022;13:256.","journal-title":"Front Immunol"},{"key":"2638_CR10","doi-asserted-by":"publisher","first-page":"110336","DOI":"10.1016\/j.ejrad.2022.110336","volume":"152","author":"S Mezghani","year":"2022","unstructured":"Mezghani S, Salga M, Tordjman M, Amar R, Carlier R-Y, Chiche L. Heterotopic ossification and COVID 19: imaging analysis of ten consecutive cases. Eur J Radiol. 2022;152:110336.","journal-title":"Eur J Radiol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02638-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02638-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02638-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T08:05:57Z","timestamp":1679299557000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02638-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,20]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2638"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02638-0","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,20]]},"assertion":[{"value":"6 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board at the University of California (approval #20-30734). Subjects were consented to this protocol.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable, as no individual data is presented.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ECH serves in a volunteer capacity on the Medical Registry Advisory Board of the International Fibrodysplasia Ossificans Progressiva Association. ECH also serves in a volunteer capacity on the Fibrous Dysplasia Foundation Medical Advisory Board. ECH is a member of the International Clinical Council on FOP. ECH received clinical trials support through his institution\u00a0from Clementia Pharmaceuticals, an Ipsen Company; and Ultragenyx, Inc., for studies unrelated to this project. These pose no conflicts for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}